Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siponimod

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

- PMLiVE

Alcon spun off, leaner Novartis raises profit forecast

Expects three new launches in 2019

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

- PMLiVE

Novartis makes case for gene therapy Zolgensma in SMA

New data revealed ahead of FDA review

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

- PMLiVE

Trump takes aim at Obamacare with repeal move

Aims to dismantle the programme

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links